Maggie Chen, AGC Biologics' Sr. Director of Manufacturing, will be presenting during this event on the advancements in cell and gene therapies. We hope you'll join us at this amazing event to explore new discoveries in regenerative medicine and clinical trials in this one-day conference.
AGC Biologics’ cell therapy services support every stage of the product journey, from pre-clinical through commercialization. At our Milan and Longmont facilities, we can work with virtually any cell type – including Human Mesenchymal Stem Cells (hMSCs), Exosomes, CD34+, T-Cells, NK Cells, and more.
Using the latest autologous and allogeneic methods, we help your products meet the exact specifications for patients in a clinical or commercial setting.
AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). Our sites in the U.S. and Italy have supported four commercial products.
Our ready-to-use platform capabilities for AAV and LVV programs are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house.
To support your pDNA needs, AGC Biologics utilizes a customized process based on your specific plasmid and hosting system. We have extensive technical expertise in fermentation, purification, and analytics, and our highly experienced teams routinely manufacture GMP-grade pDNA materials. This work includes starting material for gene therapy, and viral vector manufacturing.